Removing  barriers to recovery after neurotrauma

BioAxone’s scientific team has unmatched knowledge and a deep understanding of Rho signaling pathways, axon regeneration, and neurotrauma. This knowledge and understanding emanates from over 20 years of research led by our founder into the key signaling pathways and proteins that inhibit axon regeneration after spinal cord injury. The spinal cord is not hard wired and “learning” can occur in spinal cord circuits. Drugs that promote axon regeneration stimulate natural repair processes, and maximizing function after neurotrauma is most achievable with drugs that enhance connectivity. BioAxone’s work has demonstrated that Rho is a key, if not the key, to impact regeneration and repair. This target is at the core of our out-licensed biologic drug VX-210.

Our second-generation drugs, Rho kinase (ROCK) inhibitors, have the potential to extend the window of treatment after spinal cord injury to promote axon regeneration, and to heal the broken blood brain barrier. We also have a new drug in development to reduce expression of  PTEN, a key  target to overcome intrinsic barriers to regeneration.

ROCK is hyper-activated in endothelial cells in neurovascular disorders, including the disease of cerebral cavernous malformation (CCM). Cerebral cavernous malformation is a serious genetic disease where endothelial lesion in the brain become leaky and bleed. There is no treatment for CCM except invasive surgery. ROCK is a target for treatment because the genetic mutation leading to CCM causes ROCK hyper-activation in brain capillary endothelial cells. Treatments effective for CCM may also have utility in treating the blood brain defect in other neurovascular disorders, such as stroke.

bbb-picture